Sugi Predict

Sugi Predict / Compounds / SCHEMBL1891050

SCHEMBL1891050

SCHEMBL1891050

Fc1cc(Cc2c[nH]c3ncc(Cl)cc23)cnc1NCc1ccc(C(F)(F)F)nc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 5/20 1.00
▸ CYP3A4 P08684 11/20 0.76
▸ CSF1R P07333 3/20 0.75
▸ KIT P10721 2/20 0.75
▸ LCK P06239 1/20 0.75
▸ PGR P06401 1/20 0.75
▸ CHRM2 P08172 1/20 0.75
▸ HTR1A P08908 1/20 0.75
▸ ADRA2A P08913 1/20 0.75
▸ PDGFRB P09619 1/20 0.75
▸ ADORA3 P0DMS8 1/20 0.75
▸ CHRM1 P11229 1/20 0.75
▸ PDGFRA P16234 1/20 0.75
▸ FLT1 P17948 1/20 0.75
▸ DRD1 P21728 1/20 0.75
▸ TBXA2R P21731 1/20 0.75
▸ SLC6A2 P23975 1/20 0.75
▸ ADORA1 P30542 1/20 0.75
▸ SLC6A4 P31645 1/20 0.75
▸ ADRA1A P35348 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30170549 0.90 CYP2C9 (0.81) CYP2C9CYP3A4CSF1RKITLCK
SCHEMBL1889776 0.89 CYP2C9 (1.00) CYP2C9CYP3A4CSF1RKITLCK
SCHEMBL1266891 0.87 CSF1R (0.81) CYP2C9CYP3A4CSF1RKITLCK
SCHEMBL1882576 0.86 CYP3A4 (1.00) CYP2C9CYP3A4CSF1RKITLCK
Pexidartinib SCHEMBL1267310 0.85 CSF1R (1.00) CYP2C9CYP3A4CSF1RKITLCK
Pexidartinib SCHEMBL29361827 0.85 CSF1R (1.00) CYP2C9CYP3A4CSF1RKITLCK
Pexidartinib SCHEMBL29380288 0.85 CSF1R (1.00) CYP2C9CYP3A4CSF1RKITLCK
Pexidartinib SCHEMBL29772694 0.85 CSF1R (0.98) CYP2C9CYP3A4CSF1RKITLCK
Pexidartinib SCHEMBL29360304 0.85 CSF1R (0.98) CYP2C9CYP3A4CSF1RKITLCK
Pexidartinib SCHEMBL18207396 0.85 CSF1R (0.98) CYP2C9CYP3A4CSF1RKITLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2496086-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2012-09-12 — — EP claimed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 — — WO claimed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 — — US claimed
EP-4295912-A2 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Daiichi Sankyo, Inc. (US) 2023-12-27 — — EP disclosed
US-10123998-B2 Kinase modulation, and indications therefor PLEXXIKON INC. (US) 2018-11-13 — — US disclosed
US-20180055828-A1 KINASE MODULATION, AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2018-03-01 — — US disclosed
US-9730918-B2 Kinase modulation, and indications therefor PLEXXIKON INC. (US) 2017-08-15 — — US disclosed
US-20160243092-A1 KINASE MODULATION, AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2016-08-25 — — US disclosed
US-9358235-B2 Kinase modulation, and indications therefor PLEXXIKON INC. (US) 2016-06-07 — — US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 — — US disclosed
US-9096593-B2 Compounds and methods for kinase modulation, and indications therefor PLEXXIKON INC. (US) 2015-08-04 — — US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 — — US disclosed
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON INC. (US) 2014-02-13 — — US disclosed
US-20140037617-A1 KINASE MODULATION, AND INDICATIONS THEREFOR DAIICHI SANKYO, INC. 2014-02-06 — — US disclosed
EP-2496086-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR Plexxikon, Inc. (US) 2012-09-12 — — EP disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 — — WO disclosed
WO-2011057022-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. (US) 2011-05-12 — — WO disclosed
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR PLEXXIKON, INC. 2011-05-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10123998-B2 Kinase modulation, and indications therefor FLT3, FLT4, FLT1 CYP2C9 4286/4885CYP3A4 4236/4885CSF1R 147/4885
US-20140037617-A1 KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, FLT4, FLT1 CYP2C9 4286/4885CYP3A4 4236/4885CSF1R 147/4885
US-20110112127-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP2C9 3884/4885CYP3A4 3717/4885CSF1R 154/4885
US-20160243092-A1 KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, FLT4, FLT1 CYP2C9 4286/4885CYP3A4 4236/4885CSF1R 147/4885
US-20180055828-A1 KINASE MODULATION, AND INDICATIONS THEREFOR FLT3, FLT4, FLT1 CYP2C9 4286/4885CYP3A4 4236/4885CSF1R 147/4885
US-20140045840-A1 COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR KIT, FLT3, BRAF CYP2C9 3884/4885CYP3A4 3717/4885CSF1R 154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.